Dongyangguang Changjiang Pharmaceutical (01558) rose more than 8% after profit. As of press release, it rose 7.51% to HK$10.7, with a turnover of HK$711 million.
The Zhitong Finance App learned that Dongyangguang Changjiang Pharmaceutical (01558) rose more than 8% after Yingxi. As of press release, it had risen 7.51% to HK$10.7 million, with a turnover of HK$711 million.
According to the news, Dongyang Changjiang Pharmaceutical announced Yingxi. The Group's annual turnover for 2023 is estimated to be about RMB 6.295 billion, an increase of about 68.09% over the previous year; net profit to mother is about RMB 1.9 billion to RMB 2.1 billion, an increase of about 2367.53% to 2627.27% over the previous year. Mainly due to the gradual improvement in social and economic performance, the normalization of personnel turnover and daily social activities. Coupled with the Group's strengthening of academic promotion and brand building this year, the brand awareness of the Group's core product, Kewei, was further enhanced.
Notably, Dongyangguang Changjiang Pharmaceutical recently announced that its direct shareholder Hong Kong Dongyangyang transferred 25.71% of its shares to Guangdong Dongyangyang Pharmaceutical, with a total consideration of HK$2,067 billion. Furthermore, the company learned that the parent company Guangdong Dongyangguang Pharmaceutical is considering absorbing and merging the company through a share exchange, and will use the new H shares listed on the main board of the Stock Exchange in the form of an introduction as a cancellation price. Once the possible merger is completed, the company's listing status on the Stock Exchange will be cancelled. The possible merger and possible listing are still in the preliminary stages, and it is difficult to determine whether they will proceed.